Topic

Articles

Samsung Biologics is planning to construct a new manufacturing facility in Incheon, South Korea, that will offer multi-product manufacturing, including cell and gene therapies and next-gen vaccines.

Samsung Biologics to Construct New Manufacturing Facility for Next-Gen Vaccines and CGT

In their collaboration, Bristol Myers Squibb and Prellis Biologics aim to generate human antibody libraries for select targets to enable drug discovery.

Bristol Myers Squibb and Prellis Biologics Partner to Build Human Antibody Libraries

After a previously announced merger, Protagen Protein Services, BioAnalytix, and GeneWerk have formed a new CRO under the name ProtaGene.

Protagen Protein Services, BioAnalytix, and GeneWerk Combine to Form New CRO, ProtaGene 

Pfizer will pay Beam $300 million upfront to conduct research on three undisclosed base editing targets in the liver, muscle, and central nervous system.

Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration

Fosun Pharma and Insilico Medicine will collaborate on AI-driven drug discovery and development of product candidates targeting multiple disease targets.

Fosun Pharma and Insilico Medicine Partner on Drug Discovery and Development Using Artificial Intelligence

The collaboration between Bristol Myers Squibb and Century Therapeutics will combine Century’s iPSC-derived allogeneic cell therapy platform with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development.

Bristol Myers Squibb and Century Therapeutics to Collaborate on Developing iPSC-derived Allogeneic Cell Therapies

Fujifilm Diosynth Biotechnologies' 89,000 square-foot expansion of its BioProcess Innovation Center in Research Triangle Park, N.C., will double its capacity to support process characterization.

Fujifilm Grows Lab Space at North Carolina Facility

Luc Gagnon, PhD, is vice-president of Vaccine Sciences at Nexelis.

The COVID-19 pandemic generated partnerships among organizations with the goal of changing the way in which assay development and tech transfer of these assays are conducted moving forward.

Elements that are Key for Successful Assay Transfer

Feliza Mirasol is the science editor for 

The urgency with which COVID-19 forced the biopharma industry to produce therapies has refocused the search for new tools to enable rapid therapeutic responses to a pandemic.

COVID Pandemic Prompts Renewed Interest in Biotech Startups

The collaboration will leverage Alynlam’s proprietary small interfering RNA (siRNA) technology to inhibit a target discovered by Novartis.

BioBusiness